Progen gets in synth

By Dylan Bushell-Embling
Wednesday, 02 July, 2008

Brisbane biotech Progen Pharmaceuticals (ASX: PGL) has spun out its manufacturing business into a wholly-owned subsidiary.

The new subsidiary will be called PharmaSynth, and will be responsible for completing Progen's PI-88 manufacturing process.

It will also offer process development and manufacturing services to the biotechnology industry.

Progen's former director of manufacturing operations, Les Tillack, is the new company's CEO.

Related News

Unhealthy Western diet could accelerate cognitive decline

An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...

Cancer drug enters clinical trials based on a false mechanism

A cancer drug currently being tested in patients appears to have entered clinical trials based on...

Russia insists there is "no plague case" following lab worker death

Russian health authorities say there is no evidence that pneumonic plague played a part in the...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd